Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

NCT06316960 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

AML, Childhood
Relapse/Recurrence
Refractory AML
Core Binding Factor Acute Myeloid Leukemia
C-KIT Mutation

Interventions

DRUG: Avapritinib
DRUG: Azacitidine Injection
DRUG: Decitabine Injection
DRUG: Idarubicin Hydrochloride
DRUG: Cytarabine
DRUG: Granulocyte Colony-Stimulating Factor

Sponsor

Children's Hospital of Soochow University